-
公开(公告)号：US4803613A
公开(公告)日：1989-02-07
申请号：US860430
申请日：1986-05-07
IPC分类号： G05B15/02 , G05B19/414 , G06F15/46 , G06F9/40 , G06F15/16
CPC分类号： G05B19/4141 , B65G2207/14 , G05B2219/32052 , G05B2219/33156 , G05B2219/33342 , G05B2219/33344 , G05B2219/34367 , G05B2219/34418 , G05B2219/35243
摘要： A control apparatus for controlling a controlled object including controlled elements comprises a host processor, a plurality of slave modules and a communication network for providing communication between the host processor and the slave modules. The host processor interprets a control program to generate commands for the controlled elements in response to demands send from the slave modules. These commands are sent via the communication network to the respective slave modules. Each slave module is allotted to a controlled element and has a processor which interprets and executes the commands for its allotted controlled element and generates a demand upon finishing the execution of a command. This demand is sent via the communication network to the host processor and causes the next command to be generated.
摘要翻译： 用于控制受控对象的控制装置包括受控元件包括主机处理器，多个从模块和用于在主机处理器和从模块之间提供通信的通信网络。 主处理器解释控制程序以响应于从从模块发送的请求而产生受控元件的命令。 这些命令通过通信网络发送到相应的从模块。 每个从模块被分配给受控元件，并且具有处理器，其解释并执行其分配的受控元件的命令，并且在完成命令的执行时产生需求。 该需求通过通信网络发送到主机处理器，并且导致下一个命令被产生。
-
公开(公告)号：US20110077195A1
公开(公告)日：2011-03-31
申请号：US12848638
申请日：2010-08-02
摘要： An effective liquid preparation achieves high bioavailability (BA) of physiologically active peptides or proteins, including ghrelins, that are administered as drugs. Also provided is a method for improving the BA of physiologically active peptides or proteins, including ghrelins, that are subcutaneously injected in aqueous solutions. The liquid preparation contains: a physiologically active peptide or protein, such as ghrelins, as an active ingredient; an acid solution including one or a combination of two or more selected form the group consisting of acetic acid, lactic acid, phosphoric acid, glycine, citric acid, hydrochloric acid, propionic acid, butyric acid, benzoic acid and salts thereof; an alcohol; and a polar organic liquid including one or a combination of two or more selected from the group consisting of N-methyl-2-pyrrolidone, dimethylformamide, dimethylsulfoxide and methylparaben.
摘要翻译： 有效的液体制剂实现了作为药物施用的生理活性肽或蛋白质（包括生长素释放肽）的高生物利用度（BA）。 还提供了一种用于改善皮下注射在水溶液中的生理活性肽或蛋白质（包括生长素释放肽）的BA的方法。 液体制剂含有：生理活性肽或蛋白质，如生长素释放肽，作为活性成分; 包括选自乙酸，乳酸，磷酸，甘氨酸，柠檬酸，盐酸，丙酸，丁酸，苯甲酸及其盐中的一种或两种以上组合的酸溶液; 酒精; 以及包含选自N-甲基-2-吡咯烷酮，二甲基甲酰胺，二甲基亚砜和对羟基苯甲酸甲酯中的一种或两种以上的组合的极性有机液体。
-
公开(公告)号：US20080193997A1
公开(公告)日：2008-08-14
申请号：US11660406
申请日：2005-08-24
IPC分类号： C12N9/94
摘要： An effective liquid preparation achieves high bioavailability (BA) of physiologically active peptides or proteins, including ghrelins, that are administered as drugs. Also provided is a method for improving the BA of physiologically active peptides or proteins, including ghrelins, that are subcutaneously injected in aqueous solutions. The liquid preparation contains: a physiologically active peptide or protein, such as ghrelins, as an active ingredient; an acid solution including one or a combination of two or more selected form the group consisting of acetic acid, lactic acid, phosphoric acid, glycine, citric acid, hydrochloric acid, propionic acid, butyric acid, benzoic acid and salts thereof; an alcohol; and a polar organic liquid including one or a combination of two or more selected from the group consisting of N-methyl-2-pyrrolidone, dimethylformamide, dimethylsulfoxide and methylparaben.
摘要翻译： 有效的液体制剂实现了作为药物施用的生理活性肽或蛋白质（包括生长素释放肽）的高生物利用度（BA）。 还提供了一种用于改善皮下注射在水溶液中的生理活性肽或蛋白质（包括生长素释放肽）的BA的方法。 液体制剂含有：生理活性肽或蛋白质，如生长素释放肽，作为活性成分; 包括选自乙酸，乳酸，磷酸，甘氨酸，柠檬酸，盐酸，丙酸，丁酸，苯甲酸及其盐中的一种或两种以上组合的酸溶液; 酒精; 以及包含选自N-甲基-2-吡咯烷酮，二甲基甲酰胺，二甲基亚砜和对羟基苯甲酸甲酯中的一种或两种以上的组合的极性有机液体。
-
4.发明授权Motilin-like peptide compound having transmucosal absorbability imparted thereto 有权具有经粘膜吸收性的胃动素肽类化合物公开(公告)号：US08710184B2
公开(公告)日：2014-04-29
申请号：US13388021
申请日：2010-07-29
申请人： Seiji Sato , Takeshi Hanada , Naomi Wakabayashi , Yutaka Masuda , Yuriko Harada
发明人： Seiji Sato , Takeshi Hanada , Naomi Wakabayashi , Yutaka Masuda , Yuriko Harada
摘要： The present invention aims at providing motilin-like peptide compounds that maintain the gastrointestinal motility stimulating activity of native motilin and which are adapted to have higher absorbability upon transmucosal administration. Motilin derivatives were designed and synthesized in consideration of the pathway for the degradation of motilin at a site of its transmucosal absorption and the maintenance of motilin's physiological activity and compounds characterized by substitutions for the amino acid at position 21 of native motilin have been found to show higher absorbability upon transmucosal administration and yet maintain the same activity as motilin.
摘要翻译： 本发明的目的在于提供维持天然胃动素的胃肠动力刺激活性的胃动素样肽化合物，其适于在经粘膜给药时具有较高的吸收性。 考虑到胃粘蛋白在其经粘膜吸收部位的降解途径和维持胃动素生理活性的途径，Motilin衍生物的设计和合成，已发现天然胃动素21位氨基酸的取代为特征的化合物 经粘膜给药后的吸收能力较高，但仍维持与胃动素相同的活性。
-
公开(公告)号：US5493766A
公开(公告)日：1996-02-27
申请号：US118217
申请日：1993-09-09
申请人： Shin-ichiro Yamakawa , Takeshi Hanada , Toshiyuki Tsuge , Kenichi Takakura , Masahiro Takeda , Kenzo Yamaguchi , Takemi Suzuki
发明人： Shin-ichiro Yamakawa , Takeshi Hanada , Toshiyuki Tsuge , Kenichi Takakura , Masahiro Takeda , Kenzo Yamaguchi , Takemi Suzuki
CPC分类号： C21D7/13 , C21D9/0081 , C21D2211/002 , Y10T29/49988 , Y10T29/49991
摘要： A process for hot working a continuous-cast bloom or a steel ingot, the process comprising the steps of: (1) cooling a bloom produced by continuous casting or a steel ingot produced with a mold to bring the surface temperature thereof to 50.degree. to 150.degree. C. higher than the Ar.sub.3 transformation point thereof; (2) quenching the bloom or the steel ingot in such a way that its interior remains red hot while the surface is transformed to have a bainite structure; and (3) heating the bloom or the steel ingot in a furnace followed by hot shaping.
摘要翻译： 一种用于对连续铸造的坯料或钢锭进行热加工的方法，该方法包括以下步骤：（1）冷却通过连续铸造产生的坯料或用模具生产的钢锭，使其表面温度为50℃至 比其Ar3相变点高150℃; （2）以使其内部保持红热同时将表面转化为具有贝氏体结构的方式淬火大块或钢锭; 和（3）在炉中加热花岗岩或钢锭，然后热成型。
-
公开(公告)号：US08969298B2
公开(公告)日：2015-03-03
申请号：US12848638
申请日：2010-08-02
IPC分类号： A61K38/02 , A61K9/00 , A61K38/25 , A61K47/10 , A61K47/12 , A61K47/22 , A61K47/26 , A61K47/40
摘要： An effective liquid preparation achieves high bioavailability (BA) of physiologically active peptides or proteins, including ghrelins, that are administered as drugs. Also provided is a method for improving the BA of physiologically active peptides or proteins, including ghrelins, that are subcutaneously injected in aqueous solutions. The liquid preparation contains: a physiologically active peptide or protein, such as ghrelins, as an active ingredient; an acid solution including one or a combination of two or more selected form the group consisting of acetic acid, lactic acid, phosphoric acid, glycine, citric acid, hydrochloric acid, propionic acid, butyric acid, benzoic acid and salts thereof; an alcohol; and a polar organic liquid including one or a combination of two or more selected from the group consisting of N-methyl-2-pyrrolidone, dimethylformamide, dimethylsulfoxide and methylparaben.
摘要翻译： 有效的液体制剂实现了作为药物施用的生理活性肽或蛋白质（包括生长素释放肽）的高生物利用度（BA）。 还提供了一种用于改善皮下注射在水溶液中的生理活性肽或蛋白质（包括生长素释放肽）的BA的方法。 液体制剂含有：生理活性肽或蛋白质，如生长素释放肽，作为活性成分; 包括选自乙酸，乳酸，磷酸，甘氨酸，柠檬酸，盐酸，丙酸，丁酸，苯甲酸及其盐中的一种或两种以上组合的酸溶液; 酒精; 以及包含选自N-甲基-2-吡咯烷酮，二甲基甲酰胺，二甲基亚砜和对羟基苯甲酸甲酯中的一种或两种以上的组合的极性有机液体。
-
7.发明申请COMPOSITION FOR MUCOSAL ADMINISTRATION CONTAINING AGENT FOR ENHANCING MUCOSAL ABSORPTION OF PEPTIDE DRUG, AND ADMINISTRATION METHOD THEREOF 审中-公开用于增强胶原蛋白吸收肽肽药物的包含药物的组合物的组合物及其施用方法公开(公告)号：US20110165195A1
公开(公告)日：2011-07-07
申请号：US12602576
申请日：2008-06-27
申请人： Masuo Kondoh , Hiroshi Uchida , Takeshi Hanada , Masato Hoshino
发明人： Masuo Kondoh , Hiroshi Uchida , Takeshi Hanada , Masato Hoshino
CPC分类号： A61K38/29 , A61K9/0019 , A61K9/0043 , A61K9/0073 , A61K38/164 , A61K38/2214 , A61K38/25 , A61K47/42 , A61K2300/00
摘要： A mucosal absorption-enhancing agent is provided that enables oral, nasal or pulmonary administration of peptide drugs whose administration route has heretofore been limited to the injections due to their poor absorption from the mucosa. Specifically, the mucosal absorption of peptide drugs via intestinal, pulmonary or nasal route can be enhanced by allowing the peptide drugs with the C-terminal fragment (C-CPE) of an enterotoxin (CPE) produced by the bacterium Clostridium perfringens of the genus Clostridium, in particular with the C-CPE or its mutants resulting from the substitution and/or deletion of one or several amino acid residues of the C-CPE to act thereon. The composition for mucosal administration of the present invention significantly enhances absorption of peptide drugs, such as human parathyroid hormone hPTH(1-34), human ghrelin and human motilin, through the mucosa of small intestine, lung, nasal cavity and other mucosa. Also, unlike any of the conventional mucosal absorption-enhancers, the composition for mucosal administration of the present invention does not cause tissue damage and is therefore highly safe for use.
摘要翻译： 提供了一种粘膜吸收增强剂，其能够口服，鼻或肺给予肽药物，其药物途径迄今为止由于其对粘膜的吸收差而限于注射。 具体地说，可以通过使具有由梭菌属产气荚膜梭菌（Clostridium perfringens）产生的肠毒素（CPE）的C末端片段（CPE）的C末端片段（CPE）的肽药物与肽药物的粘膜吸收， 特别是C-CPE或其由C-CPE的一个或几个氨基酸残基的取代和/或缺失产生的突变体作用于其上。 本发明的粘膜给药组合物通过小肠，肺，鼻腔和其他粘膜的粘膜显着增强肽药物如人甲状旁腺激素hPTH（1-34），人生长素释放肽和人胃动素的吸收。 此外，与任何常规的粘膜吸收增强剂不同，本发明的粘膜给药用组合物不会引起组织损伤，因此高度安全使用。
-
公开(公告)号：US4772996A
公开(公告)日：1988-09-20
申请号：US36862
申请日：1987-04-09
申请人： Hiroyuki Hanei , Takeshi Hanada , Kenji Kubo , Masahiko Watanabe , Tsutomu Omae , Toshihiko Matsuda
发明人： Hiroyuki Hanei , Takeshi Hanada , Kenji Kubo , Masahiko Watanabe , Tsutomu Omae , Toshihiko Matsuda
IPC分类号： H02M7/5387 , H02M7/537
CPC分类号： H02M7/53873
摘要： A PWM inverter includes a plurality of arms connected in parallel with a d.c. power source. Each arm is constituted by an upper arm and a lower arm each having a switching element. A plurality of switching control signals are continuously and alternately applied to one and the other of the two switching elements constituting the same arm respectively. In the PWM inverter, shunt resistors are connected between a minus terminal of the d.c. power source and the lower arms respectively. The PWM inverter further comprises a waveform command generating circuit generating commands representative of current waveforms to be supplied to a load, a carrier wave generating circuit and sample-hold circuits. Each of the sample-hold circuits samples and holds a terminal voltage of the associated shunt resistor in synchronism with the period of the carrier wave generated from the carrier wave generating circuit and at specific timing in a conduction period of the associated switching element.
摘要翻译： PWM逆变器包括与直流电路并联连接的多个臂。 能量源。 每个臂由具有开关元件的上臂和下臂构成。 多个开关控制信号分别连续交替地施加到构成相同臂的两个开关元件中的一个和另一个。 在PWM逆变器中，分流电阻连接在直流负载端子之间。 电源和下臂。 PWM逆变器还包括产生表示要提供给负载的电流波形的指令的波形指令产生电路，载波发生电路和采样保持电路。 每个采样保持电路与从载波产生电路产生的载波的周期和相关的开关元件的导通周期中的特定定时同步地采样并保持相关联的分流电阻器的端子电压。
-
9.发明申请MOTILIN-LIKE PEPTIDE COMPOUND HAVING TRANSMUCOSAL ABSORBABILITY IMPARTED THERETO 有权具有转移吸收能力的类似地胶的化合物公开(公告)号：US20120129762A1
公开(公告)日：2012-05-24
申请号：US13388021
申请日：2010-07-29
申请人： Seiji Sato , Takeshi Hanada , Naomi Wakabayashi , Yutaka Masuda , Yuriko Harada
发明人： Seiji Sato , Takeshi Hanada , Naomi Wakabayashi , Yutaka Masuda , Yuriko Harada
摘要： The present invention aims at providing motilin-like peptide compounds that maintain the gastrointestinal motility stimulating activity of native motilin and which are adapted to have higher absorbability upon transmucosal administration.Motilin derivatives were designed and synthesized in consideration of the pathway for the degradation of motilin at a site of its transmucosal absorption and the maintenance of motilin's physiological activity and compounds characterized by substitutions for the amino acid at position 21 of native motilin have been found to show higher absorbability upon transmucosal administration and yet maintain the same activity as motilin.
摘要翻译： 本发明的目的在于提供维持天然胃动素的胃肠动力刺激活性的胃动素样肽化合物，其适于在经粘膜给药时具有较高的吸收性。 考虑到胃粘蛋白在其经粘膜吸收部位的降解途径和维持胃动素生理活性的途径，Motilin衍生物的设计和合成，已经发现天然胃动素21位氨基酸的取代为特征 经粘膜给药后的吸收能力较强，但维持与胃动素相同的活性。
-
-
-
-
-
-
-
-
搜索结果
9 条记录 (耗时 0.026 秒)
